Allogene reports Q3 net loss of $83.1M; initiates first allogeneic CAR T Phase 2 trial

Allogene Therapeutics, Inc.

2022-Q3 EPS reported -$1.67 revenue$196,000

Net loss $83.1M ($0.58/share); R&D expenses $63.6M; G&A $18.9M.
Cash & investments $637M at Sep 30; 2022 cash burn guidance <$250M.
Initiated ALPHA2 Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma.
R&D Showcase on Nov 29, 2022 to feature updated CD19 and BCMA data.
FY 2022 GAAP operating expenses slightly below prior $360M-$390M guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Allogene Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $83.1 million, EPS $0.58 per share.

Period: the quarter ended September 30, 2022
Net income: $83.1 million
EPS: $0.58 per share
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2022 was $83.1 million, or $0.58 per share

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-22-000081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.